These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17074775)

  • 21. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies.
    Anker SD; Ponikowski P; Mitrovic V; Peacock WF; Filippatos G
    Eur Heart J; 2015 Mar; 36(12):715-23. PubMed ID: 25670819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database.
    Costanzo MR; Johannes RS; Pine M; Gupta V; Saltzberg M; Hay J; Yancy CW; Fonarow GC
    Am Heart J; 2007 Aug; 154(2):267-77. PubMed ID: 17643575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial.
    Triposkiadis FK; Butler J; Karayannis G; Starling RC; Filippatos G; Wolski K; Parissis J; Parisis C; Rovithis D; Koutrakis K; Skoularigis J; Antoniou CK; Chrysohoou C; Pitsavos C; Stefanadis C; Nastas J; Tsaknakis T; Mantziari L; Giannakoulas G; Karvounis H; Kalogeropoulos AP; Giamouzis G
    Int J Cardiol; 2014 Mar; 172(1):115-21. PubMed ID: 24485633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recombinant human brain natriuretic peptide on the cardiac hemodynamics and renal function in dogs with heart failure].
    Xu XW; Zeng GY; Yang Y; Liu HX
    Yao Xue Xue Bao; 2002 Oct; 37(10):758-62. PubMed ID: 12567856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ularitide: a natriuretic peptide candidate for the treatment of acutely decompensated heart failure.
    Emani S; Meyer M; Palm D; Holzmeister J; Haas GJ
    Future Cardiol; 2015 Sep; 11(5):531-46. PubMed ID: 26278236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal effects of urodilatin in healthy subjects are independent of blockade of the cyclooxygenase and angiotensin II receptor.
    Carstens J; Pedersen EB
    Scand J Clin Lab Invest; 2008; 68(1):2-10. PubMed ID: 17852806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heart failure: No effect of ularitide in heart failure outcomes.
    Fernández-Ruiz I
    Nat Rev Cardiol; 2017 Jun; 14(6):316. PubMed ID: 28470177
    [No Abstract]   [Full Text] [Related]  

  • 28. Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction.
    Gheorghiade M; Greene SJ; Ponikowski P; Maggioni AP; Korewicki J; Macarie C; Metra M; Grzybowski J; Bubenek-Turconi SI; Radziszewski W; Olson A; Bueno OF; Ghosh A; Deckelbaum LI; Li LY; Patel AR; Koester A; Konstam MA
    Eur J Heart Fail; 2013 Jun; 15(6):679-89. PubMed ID: 23471413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haemodynamic effects of hypotension induced by KRN2391 and nicardipine in isoflurane anaesthetized dogs.
    Takeda S; Ozawa Y; Tomaru T
    Can J Anaesth; 1997 Sep; 44(9):1002-7. PubMed ID: 9305565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute renal failure following cardiac surgery is reverted by administration of Urodilatin (INN: Ularitide).
    Wiebe K; Meyer M; Wahlers T; Zenker D; Schulze F; Michels P; Dalichau H; Mohr FW; Borst H; Forssmann WG
    Eur J Med Res; 1996 Feb; 1(5):259-65. PubMed ID: 9374447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic effects of milrinone with and without a bolus loading infusion.
    Baruch L; Patacsil P; Hameed A; Pina I; Loh E
    Am Heart J; 2001 Feb; 141(2):266-73. PubMed ID: 11174341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure.
    Hülsmann M; Stanek B; Frey B; Berger R; Rödler S; Siegel A; Hartter E; Schuller M; Ogris E; Pacher R
    J Heart Lung Transplant; 1997 May; 16(5):556-62. PubMed ID: 9171275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of short-term administration of recombinant human atrial natriuretic peptide (rhANP) for congestive heart failure: a phase II, multicentre randomized controlled dose-finding study.
    Wang P; Luan X; Wang G; Liu W; Zhang J; Li W; Gao X; Wang Y; Mao Y; Sun X; Wang Q; Zhang Y; Bai S
    J Clin Pharm Ther; 2013 Oct; 38(5):388-93. PubMed ID: 23672267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Neurohumoral and hemodynamic effects in combination therapy of enoximone and dopamine].
    Mitrovic V; Neuzner J; Opper H; Thormann J; Schlepper M
    Z Kardiol; 1994; 83 Suppl 2():37-48. PubMed ID: 8091823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urodilatin, a new therapy to prevent kidney failure after heart transplantation.
    Hummel M; Kuhn M; Bub A; Mann B; Schneider B; von Eickstedt KW; Forssmann WG; Hetzer R
    J Heart Lung Transplant; 1993; 12(2):209-17; discussion 217-8. PubMed ID: 8476893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute heart failure with dyspnoea: initial treatment. Furosemide and trinitrine, despite the lack of a proven survival benefit.
    Prescrire Int; 2011 Jun; 20(117):156-60. PubMed ID: 21678708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe hypotension and bradycardia after continuous intravenous infusion of urodilatin (ANP 95-126) in a patient with congestive heart failure.
    Kentsch M; Drummer C; Gerzer R; Müller-Esch G
    Eur J Clin Invest; 1995 Apr; 25(4):281-3. PubMed ID: 7601204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic use of low-dose urodilatin for prevention of renal impairment following liver transplantation: a randomized placebo-controlled study.
    Langrehr JM; Kahl A; Meyer M; Neumann U; Knoop M; Jonas S; Steinmüller T; Bechstein WO; Frei U; Forssmann WG; Neuhaus P
    Clin Transplant; 1997 Dec; 11(6):593-8. PubMed ID: 9408691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.
    Gheorghiade M; Greene SJ; Filippatos G; Erdmann E; Ferrari R; Levy PD; Maggioni A; Nowack C; Mebazaa A;
    Eur J Heart Fail; 2012 Sep; 14(9):1056-66. PubMed ID: 22713287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-effect relationships of prostaglandin E1 in severe endstage chronic heart failure.
    Stanek B; Pacher R
    Jpn Heart J; 1997 Jan; 38(1):53-65. PubMed ID: 9186281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.